We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Capsugel Completes Acquisitions of Xcelience and Powdersize

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Capsugel Completes Acquisitions of Xcelience and Powdersize"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Capsugel has announced that it has completed its acquisitions of Xcelience and Powdersize. Xcelience and Powdersize are now part of Capsugel's Dosage Form Solutions business unit, which partners with pharmaceutical and health and nutrition customers around the world to advance products through an integrated approach to the design, development and manufacture of high-quality, innovative dosage forms.

The acquisitions, announced on December 14, 2015, provide Capsugel with specialized clinical trial manufacturing and supply capabilities for a broad range of solid dosage forms; development and manufacturing for specialized products such as highly potent and controlled substance compounds; and micronization capabilities that augment the company's existing formulation design services and premier bioavailability enhancement technology platform.

When combined with Capsugel’s wide array of industry-leading hard capsule technologies, the expanded capabilities of Capsugel Dosage Form Solutions make the company better positioned than ever to partner with customers to deliver innovative, patient-centric dosage forms and solutions.